Vizora日本語

Trans Genic GroupTRANS GENIC GROUP INC.2342東証スタンダードサービス業FY ending Mar 2026, consolidated, J-GAAP

Trans Genic Group FY ending Mar 2025 results

About 85% of Trans Genic Group's sales come from Investments and Consulting business, with Drug discovery support business making up much of the rest.

It lost about ¥2 for every ¥100 of sales at the operating level.

Revenue changed -0.6% from the prior year, operating profit -390.2%.

Revenue and profit pattern

Turned to a loss

What changed from last year

FY ending Mar 2024 → FY ending Mar 2025

Revenue
-0.6%¥13.1B → ¥13B
Gross profit
-3.7%¥2.25B → ¥2.17B
Operating income
-390.2%¥89.4M → -¥259.5M
Net income attributable to owners
-26774.2%¥4.1M → -¥1.09B
Operating cash flow
Back to profit-¥392.5M → ¥94.1M
Free cash flow
Loss-¥658.1M → -¥81.4M

Where the money goes

FY ending Mar 2024 → FY ending Mar 2025

Where ¥100 of sales goes

For every ¥100 Trans Genic Group sells, how much goes where, and how much is kept.

FY ending Mar 2025
Cost of sales
¥83
SG&A
¥19
Operating loss
¥2
Net loss
¥8

Annual margin trends

Gross margin16.7%
FY ending Mar 2020: 16.1%16.1%FY ending Mar 2021: 25.1%25.1%FY ending Mar 2022: 30.5%30.5%FY ending Mar 2023: 17.5%17.5%FY ending Mar 2024: 17.2%17.2%FY ending Mar 2025: 16.7%16.7%FY20FY21FY22FY23FY24FY25
Operating margin-2.0%
FY ending Mar 2020: 1.6%1.6%FY ending Mar 2021: 8.1%8.1%FY ending Mar 2022: 14.6%14.6%FY ending Mar 2023: -0.2%-0.2%FY ending Mar 2024: 0.7%0.7%FY ending Mar 2025: -2.0%-2.0%FY20FY21FY22FY23FY24FY25
Net margin-8.4%
FY ending Mar 2020: -4.0%-4.0%FY ending Mar 2021: 4.9%4.9%FY ending Mar 2022: 14.9%14.9%FY ending Mar 2023: -3.6%-3.6%FY ending Mar 2024: 0.0%0.0%FY ending Mar 2025: -8.4%-8.4%FY20FY21FY22FY23FY24FY25

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2025

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (6)

  • EDINET (FSA Japan)

    有価証券報告書－第28期(2025/04/01－2026/03/31)

    ID S100YCRI2026-06-17Open

  • EDINET (FSA Japan)

    訂正有価証券報告書－第27期(2024/04/01－2025/03/31)

    ID S100WG8Z2025-08-01Open

  • EDINET (FSA Japan)

    有価証券報告書－第26期(2023/04/01－2024/03/31)

    ID S100TPLD2024-06-21Open

  • EDINET (FSA Japan)

    有価証券報告書－第25期(2022/04/01－2023/03/31)

    ID S100R0CX2023-06-22Open

  • EDINET (FSA Japan)

    有価証券報告書－第24期(令和3年4月1日－令和4年3月31日)

    ID S100OEUK2022-06-24Open

  • EDINET (FSA Japan)

    有価証券報告書－第23期(令和2年4月1日－令和3年3月31日)

    ID S100LOBQ2021-06-24Open

Extracted from XBRL: 51 / Derived from other figures: 2

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image